Eyenovia (NASDAQ:EYEN) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Eyenovia (NASDAQ:EYEN) announced its earnings results on Tuesday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02, Zacks reports. Eyenovia had a negative return on equity of 547.46% and a negative net margin of 116,506.25%. During the same period in the previous year, the firm posted ($0.18) earnings per share.

Eyenovia Stock Performance

NASDAQ EYEN traded down $0.10 during trading hours on Wednesday, hitting $0.41. 2,509,500 shares of the stock were exchanged, compared to its average volume of 1,199,277. Eyenovia has a 12-month low of $0.37 and a 12-month high of $2.57. The company has a quick ratio of 0.27, a current ratio of 0.46 and a debt-to-equity ratio of 3.72. The stock has a 50-day moving average of $0.51 and a 200 day moving average of $0.72. The company has a market cap of $25.94 million, a price-to-earnings ratio of -0.52 and a beta of 1.75.

Insider Transactions at Eyenovia

In related news, CEO Michael M. Rowe purchased 50,000 shares of Eyenovia stock in a transaction dated Monday, August 26th. The stock was bought at an average cost of $0.57 per share, for a total transaction of $28,500.00. Following the transaction, the chief executive officer now owns 82,927 shares in the company, valued at approximately $47,268.39. The trade was a 100.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 7.10% of the company’s stock.

Wall Street Analysts Forecast Growth

EYEN has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Eyenovia in a research report on Wednesday. William Blair upgraded Eyenovia to a “strong-buy” rating in a research report on Friday, August 30th.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.